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Abstract
Endophthalmitis means bacterial or fungal infection inside the eye involving the vitreous and/or aqueous humors. Most cases are exogenous
and occur after eye surgery, after penetrating ocular trauma, or as an extension of corneal infection. An increasing number of cases are
occurring after intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications. Endophthalmitis may also be
endogenous, arising from bacteraemic or fungaemic seeding of the eye. The infected eye never serves as a source of bacteraemia or
fungaemia, however. The most common pathogens in endophthalmitis vary by category. Coagulase-negative staphylococci are the most
common causes of post-cataract endophthalmitis, and these bacteria and viridans streptococci cause most cases of post-intravitreal anti-
VEGF injection endophthalmitis, Bacillus cereus is a major cause of post-traumatic endophthalmitis, and Staphylococcus aureus and
streptococci are important causes of endogenous endophthalmitis associated with endocarditis. In Taiwan and other East Asian nations,
Klebsiella pneumoniae causes most cases of endogenous endophthalmitis, in association with liver abscess. Endogenous fungal
endophthalmitis in hospitalized patients is usually caused by Candida species, particularly Candida albicans. Acute endophthalmitis is a
medical emergency. The most important component of treatment is the intravitreal injection of antibiotics, along with vitrectomy in severe
cases. Systemic antibiotics should be used in cases of endogenous endophthalmitis and exogenous fungal endophthalmitis, but their role in
exogenous bacterial endophthalmitis is uncertain. Repeated intravitreal injections of antibiotics may be necessary if there is no response to
the initial therapy. Many eyes that receive prompt and appropriate treatment will recover useful vision.
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Introduction
Endophthalmitis means bacterial or fungal infection inside the
eye, involving the vitreous and/or aqueous humors. Most cases
of endophthalmitis are exogenous, and organisms are intro-
duced into the eye via trauma, surgery, or an infected cornea.
Endogenous endophthalmitis occurs when the eye is seeded
via the bloodstream. Patients usually have symptoms from
their underlying systemic infection, but sometimes present
only with eye symptoms.
Endophthalmitis does not serve as a source of bactaeremia
or fungaemia. Infection remains conﬁned to the eye. In
panophthalmitis, infection spreads from the globe of the eye
to the adjacent soft tissues of the orbit.
Most cases of endophthalmitis present acutely, with hours
to a few days of symptoms. These cases are medical
emergencies, as delay in treatment may result in permanent
vision loss.
Types of Endophthalmitis
Endophthalmitis may be divided into several categories
(Table 1). Regardless of category, treatment requires the
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prompt intra-ocular injection of antibiotics and, in some cases,
a vitrectomy as well.
Acute post-cataract endophthalmitis
Cataract surgery is one of the most common eye operations
performed worldwide, and acute post-cataract endophthalm-
itis complicates this procedure in c. 0.1% of cases [1–7]. In the
USA and Europe, nearly all cases are caused by bacteria,
whereas in tropical regions such as India, 10–20% of cases are
caused by fungi [8].
Ocular surface bacteria contaminate the aqueous humor in
7–43% of cataract operations, but endophthalmitis is rare [9–
11]. This may be because the aqueous humor has a rapid
turnover time (100 min). The vitreous humor does not
regenerate, so it is more susceptible to infection. During
cataract surgery, the lens pulp is removed but the posterior
lens capsule is left intact. Inadvertent breaks in this capsule
increase the endophthalmitis risk 14-fold [6,12]. Other end-
ophthalmitis risk factors include clear corneal incision and
silicone rather than acrylic intra-ocular lenses (IOLs) [13].
Symptoms occur within 1 week postoperatively in 75% of
cases, and include decreased vision (95%), red eye (80%), and
eye pain (75%) [14]. Patients feel otherwise well and are
afebrile. On physical examination, vision is decreased, eyelids
are normal to slightly swollen, the conjunctiva is injected, and a
hypopyon is present in >80% of cases [15]. There are white
blood cells in the aqueous humor and vitreous humor, so the
view of the retina is hazy. In 80% of patients, the view is so
obscured that retinal vessels cannot be seen [16].
Diagnosis. Endophthalmitis is a clinical diagnosis, supported by
culture of intra-ocular ﬂuids, although a negative culture
occurs in 30% of cases. The differential diagnosis is sterile
intra-ocular inﬂammation. This may occur as a reaction to
surgery, and is typically greatest on the ﬁrst postoperative day,
whereas endophthalmitis usually occurs on day 2 or later.
Toxic anterior segment syndrome, another sterile inﬂamma-
tory condition, is associated with instrument-cleaning prob-
lems or with solutions used during surgery [17,18].
The vitreous humor is sampled through either a vitrectomy
or a needle aspirate; the aqueous humor is sampled through a
needle aspirate. Needle aspirates can be performed as an ofﬁce
procedure. A vitrectomy is performed in the operating room
with a vitrector, which cuts and aspirates the vitreous humor
while this is being replaced by saline. The result is c. 100 mL of
dilute vitreous washings, which may be vacuum-ﬁltered
through a 0.45-lm ﬁlter; the ﬁlter paper can then be cultured.
Gram stains are positive in 40–50% of cases. Gram stains may
reveal pigment granules from the iris or retinal pigment
epithelium, and these may resemble Gram-positive cocci but
are more refractile. Vitreous cultures are more likely to be
positive after vitrectomy than vitreous aspirate (90% vs. 75%);
aqueous cultures are positive in 40% [16]. Only the aqueous
humor is positive in 4% [19].
Molecular diagnostic techniques have been used to improve
the sensitivity of pathogen detection. A multicentre European
study of over 16 600 cataract operations evaluated 29
endophthalmitis cases by both culture and PCR, and found
that PCR increased the detection of pathogens from 14 to 20
TABLE 1. Types of endophthalmitis, common pathogens, and treatment
Type
Most common
pathogens
Intial intravitreal
treatmenta
Vitrectomy
necessaryc
Need to remove artiﬁcial
intra-ocular lens? Initial systemic antibioticsb
Acute
post-cataract
Coagulase-negative
staphylococci
(70% of cases), other
Gram-positive cocci (25%)
Intravitreal vancomycin
plus ceftazidime
Yes, if severe
infection or
fungal aetiology
No, unless fungal aetiology Value unknown, rarely given
Chronic
post-cataract
Propionibacterium acnes Intravitreal vancomycin Varies Yes No
Post-injection Coagulase-negative
staphylococci, viridans
streptococci
Intravitreal vancomycin
plus ceftazidime
Yes, if severe
infection
No Moxiﬂoxacin or similar?
Bleb-related Streptococci, Haemophilus
inﬂuenzae
Intravitreal vancomycin
plus ceftazidime
Most cases No Moxiﬂoxacin or similar?
Post-traumatic Bacillus cereus, coagulase-
negative staphylococci
(fungi in some cases)
Intravitreal vancomycin
plus ceftazidime
(plus amphotericin if
fungi suspected)
Most cases Varies (always if fungal) Intravenous vancomycin
plus either ceftazidime
or ciproﬂoxacin
Endogenous
bacterial
Staphylococcus aureus,
streptococci, Gram-
negative bacilli
(e.g. Klebsiella)
Intravitreal vancomycin
plus ceftazidime
(or amikacin)
Yes, nearly
all cases
No Intravenous antibiotics tailored
to systemic infection
Candida Candida species Intravitreal amphotericin
(or voriconazole)
Yes, if vitritis Often Yes
Mould Aspergillus, Fusarium Intravitreal amphotericin Yes Yes Yes
aIntravitreal antibiotics are given at the end of a vitrectomy case in the operating room, or as an ofﬁce procedure without a vitrectomy (see text). Whereas initial therapy is
empirical, subsequent injections may be tailored to culture results.
bSystemic antibiotics alone are not effective in treating endophthalmitis, except for most cases of Candida chorioretinitis without vitritis. They are indicated in endogenous
endophthalmitis and fungal endophthalmitis. Whether they are beneﬁcial as adjunctive therapy in exogenous bacterial endophthalmitis is unknown (see text).
cSee text for exceptions.
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[20]. In a study from France of 100 post-cataract endoph-
thalmitis cases, the sensitivities of PCR and culture were
similar with initial intra-ocular samples, before antibiotics had
been injected [21]. However, PCR was much more sensitive
than culture (70% vs. 9%) in subsequent vitrectomy samples,
reﬂecting either the inhibitory effect of the previously injected
antibiotics, or the fact that PCR does not distinguish living
from dead organisms. In a study from Brazil of 11 patients with
endophthalmitis, cultures were positive in 75% and PCR was
positive in 91% [22]. This study also tried to evaluate the
speciﬁcity of PCR; none of the 12 vitreous controls were
positive, but two of 50 aqueous samples were. A study from
Japan also found improved sensitivity with PCR: of 19 patients
with endophthalmitis, 18 were positive by PCR and only ten by
culture [23]. Control samples were positive by PCR in 6% of
50 patients with uveitis, although in none of 40 patients
without intra-ocular inﬂammation.
Microbiology. The major pathogens are coagulase-negative
staphylococci (70%), Staphylococcus aureus (10%), streptococci
(9%), other Gram-positive cocci, including enterococci and
mixed bacteria (5%), and Gram-negative bacilli (6%). The fact
that Gram-positive bacteria cause >95% of cases reﬂects the
usual pathogenesis, i.e. contamination of the aqueous humor
with surface bacteria during surgery. In tropical regions such as
India, fungi may cause 10–15% of postoperative endophthalm-
itis cases.
Treatment. The most important component of therapy is the
direct injection of antibiotics into the eye. The injection is
performed after a sample of vitreous humor is taken for Gram
staining and culture. Initially, broad-spectrum antibiotics are
used empirically: intravitreal vancomycin 1 mg/0.1 mL normal
saline plus either ceftazidime 2.25 mg/0.1 mL or amikacin
0.4 mg/0.1 mL. If there is no improvement in 48 h, a repeat
intravitreal injection may be given with either vancomycin or
ceftazidime, depending on culture results. Repeated injections of
amikacin are avoided, owing to concerns about retinal toxicity.
The second component of treatment is vitrectomy. Vitrec-
tomy surgically debrides the vitreous humor, similarly to
draining an abscess, and is the fastest way of clearing infection
in eyes with fulminant endophthalmitis. However, vitrectomy
is performed in the operating room, whereas a needle aspirate
(for culture) is performed in the ofﬁce: intravitreal antibiotics
are given at the end of a vitrectomy case or after vitreous
aspirate. A multicentre prospective trial, the Endophthalmitis
Vitrectomy Study (EVS), tried to answer the question of
whether a vitrectomy was necessary in the treatment of post-
cataract endophthalmitis, prior to intravitreal injection of
antibiotics [14]. The EVS randomized 420 patients into ‘tap’
(needle aspirate or biopsy of vitreous humor) and vitrectomy
groups, with both groups receiving intravitreal antibiotics after
the procedures [14]. Vitrectomy decreased the rate of severe
vision loss from 47% (tap group) to 20% (vitrectomy group) in
patients who presented with the worst vision (light perception
only). No apparent beneﬁt was seen in patients who presented
with hand motion or better vision, although the study design
may have obscured a possible beneﬁt: two-thirds of patients in
the ‘tap’ group actually received a vitreous ‘biopsy’ in the
operating room, with a vitrector. We favour vitrectomy for all
patients who present with severe vision loss or rapidly
worsening vision, or who are likely to have endophthalmitis
caused by virulent bacteria such as streptococci.
Systemic antibiotics are not effective in treating endoph-
thalmitis: intravitreal antibiotics must always be given.
Whether systemic antibiotics provide any additional beneﬁt
to intravitreal antibiotics is unknown. The EVS also tried to
answer this question, but the choice of systemic antibiotics
used in the study, amikacin plus ceftazidime, was poor [14].
These antibiotics have poor activity against staphylococci, the
cause of 80% of post-cataract endophthalmitis cases, and
amikacin does not cross the blood–eye barrier, and so reaches
minimal levels in the vitreous humor.
Visual outcome. The visual outcome is highly correlated with
the bacteriology. Streptococci of any type produce severe
endophthalmitis with a poor chance of visual recovery,
whereas coagulase-negative staphylococci cause milder end-
ophthalmitis in general. Overall, 50% of eyes with post-cataract
endophthalmitis recover 20/40 vision, and 10% are left with no
useful vision (5/200 or less).
Chronic post-cataract endophthalmitis
Chronic post-cataract endophthalmitis is usually caused by
Propionibacterium acnes, and presents as a persistent low-grade
inﬂammation in the anterior chamber. Patients present with
decreased vision in the affected eye, and half also have eye
pain, which is usually mild. On examination, there are white
blood cells in the aqueous humor, sometimes a hypopyon, a
characteristic white plaque on the posterior lens capsule, and
usually inﬂammation in the anterior vitreous humor.
Intra-ocular cultures may be negative, although culture of
the white capsular plaque is often positive. Treatment with a
combination of removal or exchange of the IOL, total
capsulectomy, vitrectomy and intravitreal antibiotics
(e.g. vancomycin) has been the most successful approach.
Treatment regimens that leave the original IOL in place have a
40–50% relapse rate.
In rare cases, this entity is caused by fungi, and treatment is
different (see below).
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Post-injection endophthalmitis
Intravitreal injections of anti-vascular endothelial growth factor
agents (e.g. bevacizumab, ranibizumab, and pegaptanib) are
given to treat neovascular macular degeneration. Injections may
be repeated monthly for several months, and each injection
carries a small risk of causing endophthalmitis. The number of
cases of post-injection endophthalmitis is increasing as the use
of this treatment increases, and at a tertiary eye centre in
Australia there were more cases of post-injection endoph-
thalmitis than of post-cataract endophthalmitis between 2007
and 2010 [24]. The rate of endophthalmitis per injection is low,
with reported rates varying from 0.025% to 0.2% [25–28].
A study using a Medicare database of 40 903 injections found an
endophthalmitis rate of 0.09% per injection [29].
Symptoms are eye pain and decreased vision, and exami-
nation reveals vitreal inﬂammation. In one large study, all 23
patients with presumed endophthalmitis had pain and vitritis
developing 1–6 days after injection (average: 3.4 days), and
78% had hypopyon [28]. Cultures were positive in only seven
cases. A study in England of 47 post-injection endophthalmitis
cases found that patients presented an average of 5 days after
injection (range: 1–39 days), and positive cultures occurred in
60% [25].
Gram-positive bacteria cause >95% of culture-positive cases
[30]. Coagulase-negative staphylococci cause c. 60% of cases
and viridans streptococci cause 25% [24,30]. This is a much
higher rate of streptococcal endophthalmitis than in post-
cataract cases. Viridans streptococci (Streptococcus mitis/Strep-
tococcus oralis) also caused an outbreak of 12 cases of post-
injection endophthalmitis in Florida, owing to contamination of
bevacizumab syringes made up by a single compounding
pharmacy [31]. Eleven of the 12 patients were left with
minimal vision, count ﬁngers, or worse.
Diagnosis and treatment are the same as for post-cataract
endophthalmitis (see above). Visual outcomes are poor in
cases caused by streptococci.
Bleb-related endophthalmitis
A ﬁltering bleb is a treatment for glaucoma. It is a surgically
created scleral defect, covered only with conjunctiva, that
allows excess aqueous humor to be absorbed into the
systemic circulation. Because only conjunctiva separates the
ocular surface ﬂora from the aqueous humor at the bleb,
endophthalmitis may occur at any time. The risk of endoph-
thalmitis is c. 1.3% per patient-year [32]. One study reported
an average onset at 2 years postoperatively (range: 1 month
to 8 years) [33]. Streptococci, including Streptococcus pneumo-
niae, cause 50% of cases. Haemophilus inﬂuenzae, Moraxella
catarrhalis, S. aureus and coagulase-negative staphylococci are
other pathogens [33].
Vitrectomy and intravitreal antibiotics (e.g. vancomycin plus
ceftazidime) are indicated. The value of a systemic agent as
adjunctive therapy has not been studied, but it seems
reasonable to give an oral quinolone, such as moxiﬂoxacin,
that achieves good vitreous levels and treats the major
pathogens. The visual outcome varies, depending partly on the
pathogen: 40% achieve 20/40 vision or better, whereas 30%
lose all vision in the affected eye [34].
Post-traumatic endophthalmitis
Endophthalmitis occurs in 3–10% of cases after penetrating
trauma to the eye, although early surgical repair and prophy-
lactic systemic antibiotics may reduce this incidence to <1%
[35]. Risk factors for the development of endophthalmitis
include metal rather than glass or blunt trauma injuries,
retained intra-ocular foreign bodies, disruption of the lens, and
delay in primary repair of >24 h.
Bacillus cereus is a major pathogen in post-traumatic
endophthalmitis, and causes a fulminant infection with very
poor visual outcome [36]. Onset of symptoms (eye pain, red
eye, and decreased vision) usually occurs within 12–24 h of the
injury. Findings include marked intra-ocular inﬂammation and
often a ring corneal inﬁltrate. Other causes of post-traumatic
endophthalmitis are coagulase-negative staphylococci, strep-
tococci, Gram-negative bacilli such as Klebsiella and Pseudomo-
nas, and moulds [37,38].
Treatment should be aggressive, with vitrectomy, intravi-
treal antibiotics (e.g. vancomycin plus ceftazidime), and
systemic therapy.
Endogenous bacterial endophthalmitis
Endogenous bacterial endophthalmitis arises from bacteraemic
seeding of the eye. Endocarditis, usually caused by S. aureus or
streptococci, accounts for 40% of endogenous endophthalmitis
cases in the USA, and other cases are associated with urinary
tract infections, indwelling central venous catheters, illicit
injection drug use, and procedures such as endoscopy that can
cause transient bacteraemia. In Taiwan, Singapore, and other
East Asian nations, liver abscess caused by Klebsiella pneumo-
niae is the source of 60% of cases of endogenous endoph-
thalmitis [39].
Many patients present with eye symptoms (pain and blurred
vision) rather than symptoms of their underlying infection; this
was true of half of the patients in one study [40]. Blood
cultures are positive in 75% of cases, as are vitreous cultures
[40]. Common pathogens in western countries include
S. aureus (25%), streptococci (30–50%, primarily Streptococcus
pneumoniae, Streptococcus milleri group, and group A and B
streptococci), and Gram-negative bacilli such as Escherichia coli
(30%). In Asia, K. pneumoniae causes the majority of cases.
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Treatment of the underlying source of bacteraemia with
systemic antibiotics is necessary, but this will not effectively
treat the endophthalmitis: intravitreal antibiotics and, usually, a
vitrectomy are necessary.
Candida endophthalmitis
Endogenous Candida endophthalmitis. Most cases of Candida
endophthalmitis are endogenous, occurring as a complication
of candidaemia. The candidaemia usually occurs in hospitalized
patients, often as a complication of an indwelling central
venous catheter. Other risk factors include total parenteral
nutrition, broad-spectrum antibiotics, neutropenia, recent
abdominal surgery, and glucocorticoid therapy.
Candidaemia seeds the highly vascular choroid ﬁrst, so the
initial manifestation is usually chorioretinitis or choroiditis.
There may be minimal or no vitreous inﬂammation at ﬁrst.
Infection in the choroid and retina is often painless, so, unless
the lesions are near the macula, patients with early Candida
chorioretinitis may have no symptoms. As the infection
worsens, vitritis develops, and patients develop decreased
vision. With inﬂammation spreading to the aqueous humor,
eye pain may also be a presenting symptom.
Often, the literature distinguishes Candida chorioretinitis
from Candida endophthalmitis, the latter term being reserved
for those cases with signiﬁcant vitritis. A term that includes
both Candida chorioretinitis and endophthalmitis (i.e. vitritis) is
ocular candidiasis.
The prevalence of ocular candidiasis in candidaemia must be
evaluated by prospective studies. In such studies, the incidence
varies from 2% to 26%, with most cases being attributable to
chorioretinitis and only 0–6% having signiﬁcant vitritis (i.e.
‘endophthalmitis’) [41–44]. In a multicentre trial involving 370
patients with candidaemia, possible or probable ocular
involvement occurred in 16%, with most having chorioretinitis
as the manifestation and only 1.6% being classiﬁed as having
endophthalmitis (i.e. with signiﬁcant vitritis) [41].
Outpatients may also present with endogenous Candida
endophthalmitis, and some of these patients have a recent
history of hospitalization and a recent indwelling central
venous catheter. However, most outpatients who present
with Candida endophthalmitis have a history of illicit intrave-
nous drug use. In a study from Australia, 70% of 27 patients
presenting with fungal endophthalmitis between 2001 and
2007 were injection drug users [45]. Candidaemia is often
transient in injection drug users and in patients with recent
indwelling central venous catheters, so patients may present
with decreased vision as their only symptom. They may be
misdiagnosed initially as having a sterile uveitis, unless a
history of intravenous drug use or recent hospitalization is
obtained.
The diagnosis of ocular candidiasis is made on the basis of
eye examination and conﬁrmed with vitreous culture. Vitreous
culture is usually not necessary in patients who have known
candidaemia and eye ﬁndings compatible with chorioretinitis.
Funduscopic examination shows white ﬂuffy lesions in the
choroid or retina, sometimes with vitritis (endophthalmitis).
There may be so much vitritis that the retina may be obscured.
A ‘string of pearls’ or ‘snowballs’ may be seen in the vitreous
humor, representing clumps of infection within the inﬂamed
vitreous humor. In outpatients who present with eye ﬁndings
but do not have a history of known candidaemia, diagnosis
must be suspected by clinical appearance (ﬂuffy white
inﬁltrates in the retina or vitreous humor, often with marked
vitritis), and conﬁrmed by vitreous culture.
Candida albicans is the most common cause of ocular
candidiasis, causing 92% of cases in one review; Candida
tropicalis was the second most common cause [46].
All patients with ocular candidiasis must be followed closely
by an ophthalmologist, as some patients worsen despite
therapy. In a multicentre study of 370 patients with candida-
emia who received either voriconazole or amphotericin
followed by ﬂuconazole, 18% of the 60 ocular candidiasis
cases developed while antifungal therapy was being given [41].
For most patients with chorioretinitis alone, the lesions will
respond to the systemic antifungal therapy. Patients who have
signiﬁcant vitritis (endophthalmitis) require a vitrectomy and
intravitreal amphotericin (or voriconazole), in addition to
systemic antifungal therapy with an agent that crosses the
blood–eye barrier, such as ﬂuconazole (if susceptible), voric-
onazole, or amphotericin.
Exogenous Candida endophthalmitis. Exogenous cases are rare,
and most cases occur following surgery. Inﬂammation may
initially be greatest in the anterior chamber, before involving
the vitreous humor.
Candida parapsilosis is the most common species, especially
in postsurgical outbreaks. The reason is most likely that this
species appears to survive well in irrigation ﬂuids and on
prosthetic materials [47]. An outbreak in the USA in 1983
affecting 13 patients in different states was traced to a balanced
salt solution used during ophthalmic surgery that was
contaminated during manufacture [48].
Treatment includes intra-ocular injection of either ampho-
tericin or voriconazole, vitrectomy, and systemic voriconazole
or ﬂuconazole (if the organism is susceptible). The dose of
intravitreal amphotericin is 5–10 lg in 0.1 mL of sterile water,
and the dose of intravitreal voriconazole is usually 100 lg in
0.1 mL of sterile water. If infection follows cataract surgery, it
is often necessary to remove the IOL as well. Systemic therapy
with high-dose ﬂuconazole (400–800 mg daily, assuming
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normal kidney function) is also indicated for susceptible strains,
or voriconazole for ﬂuconazole-resistant but voriconazole-
susceptible strains.
Mould endophthalmitis
Two-thirds of patients with mould endophthalmitis lose useful
vision, but the prognosis may be improving with the use of
newer antifungal agents.
Exogenous mould endophthalmitis. Mould endophthalmitis is
usually exogenous, occurring after eye surgery, after eye
trauma, or as a result of keratomycosis (fungal corneal
infection). Aspergillus and Fusarium are the most common
aetiological agents.
Postoperative mould endophthalmitis is rare in western
countries. When it does occur, it often presents subacutely,
and diagnosis may be delayed. In one review that included ten
cases of postoperative mould endophthalmitis, 60% presented
 2 months after surgery [49]. In tropical regions such as
India, moulds have caused >20% of postoperative endoph-
thalmitis cases in some series [8,50], and 80% of cases present
within 4 weeks of surgery. Outbreaks of postoperative mould
endophthalmitis have also occurred.
Post-traumatic mould endophthalmitis is also more com-
mon in India than in the USA or Europe. Moulds caused 14% of
113 culture-positive post-traumatic endophthalmitis cases in a
series from India [51]. In another series from India, the average
time to presentation after eye trauma was 7 days [52].
Aspergillus was the most common mould isolated in both of
these series.
Mould infection of the cornea (keratomycosis) may lead to
endophthalmitis as the mould grows through the cornea and
into the aqueous humor. Keratomycosis was the aetiology for
half of all exogenous mould cases in a series from Florida, and
eye surgery and trauma each accounted for 25% of cases [49].
Many cases of keratomycosis are associated with contact lens
wear. Fusarium is the most common cause of endophthalmitis
resulting from keratomycosis in many series. Some of these
cases reﬂect the international outbreak of Fusarium keratitis
that occurred in 2004–2006, related to one brand of contact
lens cleaning solution. In this outbreak, 6% of keratitis cases
developed endophthalmitis [53,54].
The clinical presentation of exogenous mould endoph-
thalmitis may be subacute, as noted above. Slit lamp exami-
nation of the eye often shows hypopyon and clumps of thick
white material in the anterior chamber, particularly after
trauma or surgery. There may be vitritis. When endophthalm-
itis complicates keratitis, slit lamp examination will show the
corneal infection, and often shows ﬁlaments extending from
the back of the cornea into the aqueous humor.
Diagnosis is made by culture of the aqueous humor as well
as the vitreous humor. Treatment requires surgery to clean
out thick material, if present, in the aqueous humor, vitrec-
tomy for signiﬁcant vitritis, intracameral and intravitreal
injections of antifungal agents (amphotericin or voriconazole),
and systemic voriconazole therapy. Systemic voriconazole
achieves very good intra-ocular levels, of c. 40% of serum
levels. Unless the fungus is known, the initial intra-ocular
injection should be amphotericin; subsequent injections may
be voriconazole for sensitive fungi. Repeated intra-ocular
injections of voriconazole (if the organism is susceptible) or
amphotericin can be given, at least 48 h apart. Voriconazole is
preferred for susceptible strains, as it appears to be less
irritating than amphotericin. If there is an IOL, this must be
surgically removed. In cases related to keratomycosis, a
corneal transplant is almost always necessary.
Several case reports have described salvage with posaco-
nazole for cases of Fusarium keratomycosis-related endoph-
thalmitis in which other therapies have failed [55,56].
Itraconazole is not recommended, as it does not achieve
good levels in the vitreous humor; and ﬂuconazole should not
be given, as it has poor activity against moulds. Systemic
amphotericin has signiﬁcant toxicity, and is rarely used to treat
exogenous fungal endophthalmitis, but may be considered as
adjunctive therapy in those rare cases of azole-resistant fungal
endophthalmitis in which other therapies have failed.
Endogenous mould endophthalmitis. Endogenous mould endoph-
thalmitis is rare. It usually occurs in severely immunocompro-
mised patients with fungaemia, or in injection drug users.
Aspergillus and Fusarium are common aetiological agents.
Hospitalized patients with mould fungaemia are usually very
ill, and may not be able to complain of eye symptoms. In a
retrospective study at a Texas cancer centre, only 27% of the
15 patients with mould endophthalmitis survived for >4 weeks
[57]. Often, the diagnosis of mould endophthalmitis is missed
during life. In an autopsy study of 85 orthotopic liver transplant
recipients, Aspergillus endophthalmitis was noted in 7%, but
only one of six patients was diagnosed ante-mortem [58]. In
contrast, injection drug users who have endogenous mould
endophthalmitis are usually well except for their eye, with no
evidence of systemic infection. In these patients, fungaemia is
usually transient, occurring only at the time of intravenous
drug injection.
In immunocompromised patients, treatment must include
systemic antifungal therapy, with the choice (e.g. amphotericin
or voriconazole) tailored to optimize treatment for the
fungaemia. Vitrectomy and removal of any IOL, followed by
intravitreal amphotericin or voriconazole (for susceptible
strains), should be performed if the patient is able to tolerate
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surgery. If too ill for surgery, the patient should have
intravitreal injection of amphotericin or voriconazole, with
repeated injections as needed. In injection drug users with no
evidence of ongoing fungaemia, vitrectomy, intravitreal anti-
fungal injection and systemic therapy should be given.
Conclusion
Endophthalmitis is a medical emergency. The most important
component of therapy is intravitreal injection of antibiotics.
Vitrectomy is also important in many cases, and leads to
improved visual outcomes in patients who present with
signiﬁcant visual loss. Vitrectomy should also be performed
in cases that have failed to respond to initial intravitreal
injection. Systemic antibiotics are necessary to treat the
underlying infection in endogenous endophthalmitis, and as
adjunctive therapy in exogenous fungal endophthalmitis. Visual
prognosis is partly related to the virulence of the pathogen.
The best outcomes usually occur in cases that are either
culture-negative or are caused by coagulase-negative staphy-
lococci, and the worst outcomes typically occur in endoph-
thalmitis caused by streptococci, Bacillus species, and moulds.
Even in cases of severe endophthalmitis caused by virulent
pathogens, however, prompt therapy may save useful vision.
Even light perception vision is considered to be useful to a
blind patient.
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